JackmanDM, ZhangY, DalbyC, et al.. Cost and survival analysis before and after implementation of Dana-Farber clinical pathways for patients with stage IV non-small-cell lung cancer. J Oncol Pract2017;13:346–352.
JackmanDM, ZhangY, DalbyC, . Cost and survival analysis before and after implementation of Dana-Farber clinical pathways for patients with stage IV non-small-cell lung cancer. J Oncol Pract 2017;13:346–352.10.1200/JOP.2017.021741)| false
HovermanJR, CartwrightTH, PattDA, et al.. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. J Oncol Pract2011;7(3 Suppl):52s–59s.
EllisPG, O’NeilBH, EarleMF, et al.. Clinical pathways; management of quality and cost in oncology networks in the metastatic colorectal cancer setting. J Oncol Pract2017:13:e522–529.
EllisPG, O’NeilBH, EarleMF, . Clinical pathways; management of quality and cost in oncology networks in the metastatic colorectal cancer setting. J Oncol Pract 2017:13:e522–529.10.1200/JOP.2016.019232)| false